A tumor-derived protein which provides T-cell costimulation through accessory cell activation

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Tumor-derived glycoprotein 90K positively influences cytotoxic effector cell generation (NK/LAK) from human peripheral blood mononuclear cells (PBMC).
• Understanding the mechanism by which 90K modulates immune responses is crucial for its therapeutic potential.

Purpose of the Study:

• To investigate the mechanism underlying 90K's effects on immune cells, specifically focusing on cytokine production and T-cell activation.
• To elucidate the role of accessory cells in 90K-mediated immune modulation.

Main Methods:

• Culturing human PBMC with 90K alone and in combination with suboptimal doses of Concanavalin A (ConA).
• Analyzing cytokine secretion (IL-2, IL-1, IL-6, GM-CSF, TNF alpha) and Intercellular Adhesion Molecule 1 (ICAM-1) expression.
• Depleting T cells and enriching for CD14+ cells to assess accessory cell and T-cell involvement.
• Evaluating the accessory function of monocytes.

Main Results:

• 90K alone did not induce IL-2 secretion but enhanced IL-2, IL-1, IL-6, GM-CSF, and TNF alpha production in the presence of suboptimal ConA.
• T-cell depletion abrogated responses to ConA and 90K, indicating 90K does not directly affect T cells.
• 90K induced cytokine production in unfractionated and CD14-enriched PBMC, and upregulated ICAM-1 on monocytic cells.
• Monocytes treated with 90K showed enhanced accessory function, promoting T-cell activation.

Conclusions:

• 90K activates accessory cells, leading to cytokine secretion and ICAM-1 expression, which act as costimulatory signals for T-cell activation.
• This mechanism amplifies cell-mediated immunity against tumor and virus-infected cells.
• 90K demonstrates potential as an immunotherapeutic agent for cancer and viral infections.